RxDoctor Payments Data

Fareed Moses Collado, MD

Interventional Cardiology · Chicago, ILNPI 1275763708

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,213 of the $42,133 with a category attached, or 64.6%. 15 manufacturers reported payments, led by Medical Device Business Services, Inc. at 58.8% of the total.

$42,133in general payments, 2019–2025

Across 154 payments — averaging $273.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$25K
  • Abbott$10K
  • Edwards Lifesciences$5K
  • Medtronic$1K
  • Boston Scientific$471
  • Abiomed$310
  • plus $421 from 9 others
$235,892in research payments, 2019–2025

Across 57 payments — averaging $4138.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$215K
  • Abbott$17K
  • Medtronic$4K

What the payments were for

  • Consulting fees$27,21365%
  • Speaking & faculty fees$2,0005%
  • Travel & lodging$5,10312%
  • Food & beverage$7,79519%
  • Entertainment$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,133 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$170,200
Medicare patients
395
Services billed
965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$57,363
JardianceEmpagliflozin26$32,970
XareltoRivaroxaban26$30,695
EntrestoSacubitril/Valsartan20$19,095
Ranolazine ErRanolazine13$1,912
Metoprolol Succinate108$1,708
Bumetanide20$1,267
Atorvastatin Calcium150$1,190
Ezetimibe33$1,031
Carvedilol82$831
ClopidogrelClopidogrel Bisulfate37$614
Losartan Potassium80$599
Amlodipine Besylate62$517
Furosemide83$491
Isosorbide Mononitrate ErIsosorbide Mononitrate30$487

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →